DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
After the April 2026 FDA ruling on compounded GLP-1, where your medication is made matters more than ever. Here is what each classification actually means.
When you order GLP-1 through a telehealth platform, the medication is made in one of a few types of pharmacy. The FDA classifies these — and the classification determines how much oversight, testing, and quality control your dose has gone through.
What it means: The drug comes directly from a company like Novo Nordisk (Wegovy, Ozempic) or Eli Lilly (Zepbound, Mounjaro). These products are subject to full FDA approval, batch testing, GMP manufacturing, and post-market surveillance.
Trust level: Highest. Every dose has been tested for identity, purity, potency, and sterility. Adverse events are tracked nationally.
What it means: An FDA-registered facility that can compound medications in large batches and ship them to providers without per-patient prescriptions. 503(b) facilities follow Current Good Manufacturing Practice (cGMP), are inspected by the FDA, and must report adverse events.
Trust level: High. Not as exhaustive as a manufacturer, but materially more oversight than traditional compounding. Look for the FDA 503(b) registration list on the FDA website.
What it means: A pharmacy that compounds medications on a per-patient-prescription basis. Regulated primarily by state boards of pharmacy, not the FDA. 503(a) cannot legally compound in bulk — though some have stretched this rule.
Trust level: Variable. Quality depends entirely on the individual pharmacy. Ask for a Certificate of Analysis on every batch.
What it means: Standard pharmacies (CVS, Walgreens, etc.) dispensing FDA-approved drugs. No compounding.
What it means: A telehealth clinic dispenses directly. Quality depends on whether they have a 503(a) or 503(b) license themselves, or contract with one.
What it means: The provider does not name the pharmacy that compounds your medication.
Trust level: Concerning. Without knowing where your dose comes from, you cannot verify quality, check for FDA actions, or escalate complaints effectively. LoseLab recommends choosing providers that disclose their pharmacy partners.
In April 2026, the FDA tightened enforcement on compounded semaglutide following the resolution of the brand-name shortage. Most 503(a) compounders can no longer legally produce compounded semaglutide for weight loss; 503(b) outsourcing facilities under certain conditions can continue, but with restrictions. This makes pharmacy classification the single most important due-diligence question to ask a telehealth provider before ordering.
We attempt to verify pharmacy classification for every brand we cover. When a provider discloses their pharmacy, we list it and cross-check it against the FDA 503(b) registration database. When a provider declines to disclose, we mark them clearly so readers can decide for themselves.